Gundgaard, Jens <br/><br/>
Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.  [electronic resource] 

 -  Primary care diabetes  Oct 2010 
 - 165-72 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-0210 
<br/><br/><label>Standard No.: </label>10.1016/j.pcd.2010.04.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Ambulatory Care--economics<br/>Chi-Square Distribution<br/>Child<br/>Child, Preschool<br/>Cost-Benefit Analysis<br/>Denmark<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Drug Costs<br/>Female<br/>General Practice--economics<br/>Health Care Costs<br/>Humans<br/>Hypoglycemic Agents--economics<br/>Infant<br/>Infant, Newborn<br/>Insulin--analogs & derivatives<br/>Insulin Detemir<br/>Insulin Glargine<br/>Insulin, Isophane--economics<br/>Insulin, Long-Acting<br/>Logistic Models<br/>Male<br/>Metformin--economics<br/>Middle Aged<br/>Models, Economic<br/>Odds Ratio<br/>Outcome and Process Assessment, Health Care--economics<br/>Pharmaceutical Services--economics<br/>Primary Health Care--economics<br/>Propensity Score<br/>Referral and Consultation--economics<br/>Registries<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult